Cannabis and hyperemesis
Browse the latest research linking medical marijuana / medicinal cannabis and hyperemesis.
Click on a study title below to open a new tab with full article, or click on a compound to see it's full list of research.
Compounds Topics Title Date
cannabis hyperemesis in humans via review (n=18) Efficacy of Capsaicin for the Treatment of Cannabinoid Hyperemesis Syndrome: A Systematic Review May 2019
Current data for capsaicin efficacy in CHS is of low methodological quality. However, the limited data on alternative antiemetic therapies and capsaicins favorable risk-benefit profile make it a reasonable adjunctive treatment option.
cannabis hyperemesis in humans via review The utility of droperidol in the treatment of cannabinoid hyperemesis syndrome Feb 2019
We reported the use of droperidol in the management of CHS. Droperidol treatment group median length of stay was significantly lower compared to the no droperidol treatment group (6.7 vs. 13.9 hours, p = .014). The most frequent dosage of droperidol used was 0.625mg intravenously.
cannabis hyperemesis via review Cannabinoid hyperemesis syndrome: An unrecognized cause of nausea and vomiting. Apr 2019
Although the definitive treatment of cannabinoid hyperemesis syndrome is discontinuing the causative agent, medical management that includes rehydration is important to prevent complications. Common antiemetic medications are ineffective, but some studies have shown haloperidol and lorazepam to be effective in treating acute symptoms.
cannabis hyperemesis via review Cannabis Hyperemesis Syndrome in Palliative Care: A Case Study and Narrative Review May 2019
The presentation of cannabis hyperemesis may be atypical in palliative care patients due to disability. More work is needed to improve risk stratification for patients using cannabis for palliative care.